» Subscribe Today!
More of what you want to know.
The Daily News
X

Forgot your password?
Skip Navigation LinksHome >
VOL. 132 | NO. 54 | Thursday, March 16, 2017

Net Loss Widens for GTx in Fourth Quarter

The Daily News

Print | Front Page | Email this story | Email reporter | Comments ()

GTx Inc. reported a fourth-quarter loss of $6.9 million, or 44 cents per share, more than twice the loss of $3.2 million from the same period in 2015.

For the year, the Memphis-based pharmaceutical company reported a net loss of $17.7 million, or $1.22 per share, down from an $18.7 million loss for all of 2015.

Research and development expenses for the quarter grew to $4.6 million, compared to $3.9 million in the fourth quarter of 2015. Similarly, full-year expenses for research and development were $17.2 million, up 26 percent from $13.6 million the previous year.

General and administrative expenses rose 9 percent to $2.3 million year-over-year in the fourth quarter, and rose by 6 percent for the full year to $8.7 million.

GTx has two clinical trials working to bring enobosarm to market as a treatment for women with advanced breast cancer, and another clinical trial with enobosarm as a potential treatment for stress urinary incontinence in postmenopausal women.

One of the enobosarm cancer trials is in Stage 2 and performing well, according to a company release. The other cancer trial could move to Stage 2 in the second quarter of 2017 if the clinical data warrants continuing to enroll patients.

Top-line results for the proof-of-concept clinical trial of enobosarm for incontinence are expected in the third quarter of 2017.

Sign-Up For Our Free Email Edition
Get the news first with our daily email


 
Blog News, Training & Events
RECORD TOTALS DAY WEEK YEAR
PROPERTY SALES 90 90 890
MORTGAGES 131 131 1,083
FORECLOSURE NOTICES 24 51 146
BUILDING PERMITS 187 319 1,524
BANKRUPTCIES 38 85 576
BUSINESS LICENSES 0 74 240
UTILITY CONNECTIONS 27 28 365
MARRIAGE LICENSES 0 0 82

Weekly Edition

Issues | About

The Memphis News: Business, politics, and the public interest.